Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases
originating from a single hematopoietic stem cell that cause excessive production of mature …

Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …

We report the clinical presentation and risk factors for survival in 175 patients with
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and …

Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

In the last years, a growing amount of evidence has been produced regarding the role of
leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms …

Interferon-alpha (rIFNα) is the only disease-modifying treatment for polycythemia vera (PV),
but whether or not it prolongs survival is unknown. This large single center retrospective …

Background Whether phlebotomy alone can adequately maintain target hematocrit in
patients with low-risk polycythemia vera (PV) remains elusive. Methods In a phase 2 open …